AN OPEN LABEL, REGISTRY STUDY OF THE SAFETY OF ILUVIEN 190 MICROGRAMS INTRAVITREAL IMPLANT IN APPLICATOR

Trial Profile

AN OPEN LABEL, REGISTRY STUDY OF THE SAFETY OF ILUVIEN 190 MICROGRAMS INTRAVITREAL IMPLANT IN APPLICATOR

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Sponsors Alimera Sciences
  • Most Recent Events

    • 23 May 2016 Interim results (n=292) published in an Alimera Sciences media release.
    • 23 May 2016 Interim data (n=292) presented at the 2016 Royal College of Ophthalmologists (RCOpth) Annual Congress, according to an Alimera Sciences media release.
    • 24 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top